Brief: Curanex Provides Operational Update On Key Regulatory Milestones
25/02/2026 13:39
Curanex Pharmaceuticals Inc CURX.O: CURANEX PROVIDES OPERATIONAL UPDATE ON KEY REGULATORY MILESTONES CURANEX PHARMACEUTICALS INC - CONTINUES TO TARGET IND SUBMISSION FOR ULCERATIVE COLITIS IN Q4 2026 Source text: ID:nGNX3XH6wm Further company coverage: CURX.O
Recent news on Curanex Pharmaceuticals
See all newsBrief: Curanex Pharmaceuticals - Securities Class Action Filed Against Curanex Pharmaceuticals And Underwriters On July 23, 2026 - SEC Filing
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Curanex Pharmaceuticals Advancing Phyto-N Toward A Planned Investigational New Drug Submission To FDA For Ulcerative Colitis In Q4 2026